Clinical trials
Brain Diseases trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
60 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2005 | 1 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 6 |
| 2019 | 2 |
| 2020 | 8 |
| 2021 | 3 |
| 2022 | 10 |
| 2023 | 6 |
| 2024 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 60 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| MicroPort NeuroTech Co., Ltd. | 3 |
| University Hospital, Clermont-Ferrand | 3 |
| Hospital Clínico Universitario de Valladolid | 2 |
| NHS Greater Glasgow and Clyde | 2 |
| Sunnaas Rehabilitation Hospital | 2 |
| University of Oxford | 2 |
| All India Institute of Medical Sciences | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Beats Medical | 1 |
| Beersheva Mental Health Center | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Brain Diseases | 60 |
| Central Nervous System Diseases | 20 |
| Nervous System Diseases | 17 |
| Stroke | 13 |
| Cerebrovascular Disorders | 12 |
| Cardiovascular Diseases | 9 |
| Cerebral Infarction | 7 |
| Vascular Diseases | 7 |
| Neurodegenerative Diseases | 6 |
| Parkinson Disease | 6 |
Trials
Showing 26 to 50 of 60. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.